ClinicalTrials.gg
Not yet recruitingNCT07686432Updated Jul 7, 2026

Effect of Circadian Rhythm on the Sedative Efficacy and Recovery Quality of Ciprofol General Anesthesia: A Multi-Center Observational Study

An observational study in Circadian Rhythm, Ciprofol and Hemodynamic Instability, sponsored by Jie Chen. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Jie Chen · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
480
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this multi-center observational study is to learn about the effect of circadian rhythm (morning vs. afternoon surgery) on the sedative efficacy, hemodynamic stability (especially induction-associated hypotension), and recovery quality of ciprofol general anesthesia in adult patients undergoing elective non-cardiac and non-cranial surgery, comparing target-controlled infusion (TCI) and non-TCI administration modes.

The main question it aims to answer is:

Does circadian rhythm (time of surgery: morning vs. afternoon) affect the sedative efficacy, incidence of induction-associated hypotension, and recovery quality of ciprofol general anesthesia? Eligible patients aged 18-65 years with ASA physical status I-II and BMI 18-30 kg/m² undergoing elective general anesthesia for non-cardiac and non-cranial surgery (duration 1-2 hours) will be grouped by anesthesia start time (morning: 08:00-11:00; afternoon: 14:00-17:00) and receive ciprofol induction and maintenance via TCI or non-TCI infusion. Perioperative data including hemodynamic changes, ciprofol dosage, recovery time, and adverse events will be recorded and analyzed.

02

Conditions studied

  • Circadian Rhythm
  • Ciprofol
  • Hemodynamic Instability
  • Anesthetics Adverse Reaction
03

In context

Lead sponsor

Jie Chen is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients scheduled for surgical procedures under general anesthesia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-65 years, with I-II.
  2. (BMI) between 18-30 kg/m².
  3. Scheduled for elective non-cardiac and non-intracranial surgery under general anesthesia, with an expected operative duration of 1-2 hours.
  4. Morning group: surgery start time between 08:00 and 11:00, with completion no later than 13:00; Afternoon group: surgery start time between 14:00 and 17:00, with completion no later than 19:00.
  5. Willing to participate and having provided signed .

Exclusion criteria

Exclusion Criteria:

  1. Severe hepatic or renal insufficiency ( Class C or \< 30 ml/min/1.73m²).
  2. Severe cardiovascular, respiratory, or neurological diseases.
  3. Long-term use of sedative-hypnotics, anxiolytics, antidepressants, or .
  4. Known allergy to ciprofol, propofol, or their .
  5. Recent (within 3 months) history of shift work, transmeridian travel, or other conditions that may cause circadian rhythm disruption.
  6. Pregnant or lactating women.
  7. Any other condition deemed by the investigator as unsuitable for participation in this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
480 participants (estimated)
Patient registry
No

Groups and cohorts

  • Morning TCI group (MT)

    The surgery start time was between 08:00 and 11:00, and the end time did not exceed 13:00. Patients in the TCI group underwent anesthetic induction and maintenance with ciprofol via target-controlled infusion (TCI) operated in Keo mode based on the effect-site target concentration (Ce).

    Other: Surgery commences in the morning.

  • Afternoon TCI group (AT)

    The surgery start time was between 14:00 and 17:00, and the end time did not exceed 19:00. Patients in the TCI group underwent anesthetic induction and maintenance with ciprofol via target-controlled infusion (TCI) operated in Keo mode based on the effect-site target concentration (Ce).

    Other: Surgery commences in the afternoon.

  • Morning non-TCI/Manual group (MC)

    The surgery start time was between 08:00 and 11:00, and the end time did not exceed 13:00.Patients in the non-TCI group undergo anesthetic induction with ciprofol via manual bolus injection.

    Other: Surgery commences in the morning.

  • Afternoon non-TCI/Manual group (AC)

    The surgery start time was between 14:00 and 17:00, and the end time did not exceed 19:00.Patients in the non-TCI group undergo anesthetic induction with ciprofol via manual bolus injection.

    Other: Surgery commences in the afternoon.

Interventions

  • OtherSurgery commences in the morning.

    The morning group was defined as patients whose surgery commenced between 08:00 and 11:00 and concluded by 13:00.

  • OtherSurgery commences in the afternoon.

    The afternoon group was defined as patients whose surgery commenced between 14:00 and 17:00 and concluded by 19:00.

06

What researchers measure

Primary outcomes

  1. Incidence of hypotension during the induction period

    The incidence of hypotension was assessed during anesthetic induction with ciprofol. Hypotension is defined as a mean arterial pressure (MAP) \< 65 mmHg at any time from the initiation of anesthetic induction to 5 minutes after tracheal intubation, and/or a MAP reduction of over 20% relative to baseline, with a duration of ≥ 1 minute.

    Time frame: From the time of initial anesthetic drug administration until 5 minutes after completion of tracheal intubation (maximum duration limited to 20 minutes)

Secondary outcomes

  1. Incidence of mean arterial pressure decreasing by >30% from baseline during the induction period and lasting for ≥1 minute.

    Incidence of mean arterial pressure decreasing by \>30% from baseline during the induction period and lasting for ≥1 minute.

    Time frame: From the time of initial anesthetic drug administration until 5 minutes after completion of tracheal intubation (maximum duration limited to 20 minutes)

  2. Incidence of MAP staying below 65 mmHg for at least 1 minute during the anesthetic maintenance

    Incidence of MAP staying below 65 mmHg for at least 1 minute throughout anesthetic maintenance

    Time frame: From 5 minutes after completion of tracheal intubation until the time of discontinuation of all anesthetic agents at the end of surgery, assessed up to 24 hours.

  3. Incidence of MAP reduction > 20% from baseline during the anesthetic maintenance period

    Incidence of MAP reduction \> 20% from baseline during the anesthetic maintenance period

    Time frame: From 5 minutes after completion of tracheal intubation until the time of discontinuation of all anesthetic agents at the end of surgery, assessed up to 24 hours.

  4. Incidence of MAP reduction > 30% from baseline during the anesthetic maintenance period

    Incidence of MAP reduction \> 30% from baseline during the anesthetic maintenance period

    Time frame: From 5 minutes after completion of tracheal intubation until the time of discontinuation of all anesthetic agents at the end of surgery, assessed up to 24 hours.

  5. Total administered dose of vasoactive agents

    Total administered dose of various vasoactive agents during the entire anesthetic period

    Time frame: From the time of initial anesthetic drug administration until the time of discontinuation of anesthetic infusion at the end of surgery,assessed up to 24 hours.

  6. Incidence of hypertension throughout anesthesia

    Incidence of hypertension throughout anesthesia.Hypertension is defined when blood pressure rises by \> 30% from baseline MAP, or SBP ≥ 160 mmHg and/or DBP ≥ 100 mmHg, and persists for ≥ 1 minute.

    Time frame: From the time of initial anesthetic drug administration until the time of discontinuation of anesthetic infusion at the end of surgery,assessed up to 24 hours.

  7. Time to successful anesthetic induction

    Time to loss of eyelash reflex following ciprofol administration

    Time frame: From the time of initial anesthetic drug administration until the time of disappearance of the patient's eyelash reflex, assessed up to 20 minutes.

  8. Time to emergence

    Time from discontinuation of anesthesia to the patient's first eye opening

    Time frame: From the time of discontinuation of anesthetic infusion until the time of the patient's first eye opening, assessed up to 2 hours.

  9. Time to extubation

    Time from discontinuation of anesthesia to tracheal extubation

    Time frame: From the time of discontinuation of anesthetic infusion until the time of tracheal tube removal, assessed up to 2 hours.

  10. Bispectral Index

    recorded BIS values at pre-induction, at loss of consciousness, at tracheal intubation, every 15 minutes intraoperatively, at the end of surgery, and at recovery of consciousness.

    Time frame: From the patient's awake state before anesthetic induction until the time when the patient emerges from anesthesia and leaves the operating room for the ward after surgery, assessed up to 24 hours.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for May 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jul 7, 2026
StartEst.
Jun 8, 2026
Primary completionEst.
May 30, 2027
CompletionEst.
May 30, 2027
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07686432
Lead sponsor
Jie Chen
Collaborators
People's Hospital of Chongqing Liangjiang New Area., Chongqing Medical University
Responsible party
Jie Chen (Chief Physician, The Second Affiliated Hospital of Chongqing Medical University) — Sponsor-investigator
First posted
Jul 7, 2026
Start date
Jun 8, 2026 (estimated)
Primary completion
May 30, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Jul 7, 2026

Study contacts

Jie Chen
Contact
305045@hospital.cqmu.edu.cn
00-86-023-13527517763

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion